AeroVanc

AeroVanc (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device. It is designed for easy self-administration.

AeroVanc is, being developed by Savara Pharmaceuticals, for the treatment of MRSA lung infection in cystic fibrosis patients and other high-risk patient populations.

Administering vancomycin into the vein (IV) can cause adverse side effects and may not reach the lungs to be able to work.

By delivering vancomycin directly to the site of infection in the lungs, AeroVanc is expected to improve how the medication works and reduce adverse effects.

AeroVanc was recently granted orphan drug status by the U.S. Food and Drug Administration.

Savara Pharmaceuticals recently completed enrollment for a Phase IIa clinical study of AeroVanc’s safety and efficacy.